海洋硫酸多糖类对糖尿病病的治疗作用
Lijuan Wu1, Xiaonan Zhang2, Jun Zhao2
1Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Yushan Road, Qingdao 266003, China; Center for Innovation Marine Drug Screening &Evaluation, Pilot National Laboratory for Marine Science and Technology (Qingdao), Qingdao 266237, China; Marine Biomedical Research Institute of Qingdao, Qingdao, 266071, China.
International journal of biological macromolecules
|January 11, 2024
概括
海洋硫酸多糖 (MSP) 显示出在治疗糖尿病病 (DN) 方面的潜力,因为它们的生物活性和结构类似于肝素硫酸盐. 本综述详细介绍了它们的抗DN效应,机制和结构-活性关系.
科学领域:
- 海洋生物学 海洋生物学
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 海洋硫酸多糖 (MSP) 是一种高分子量多糖,在海洋生物中含有硫酸盐群.
- MSP表现出多样化的生物活性,包括抗凝固剂,抗瘤,抗病毒,免疫调节和代谢调节特性.
- 它们与内源性肝素硫酸盐的结构相似性表明它们对糖尿病病 (DN) 等疾病具有治疗潜力.
研究的目的:
- 审查海洋硫酸多糖 (MSP) 的抗糖尿病病 (DN) 活动.
- 阐明MSP对DN的治疗作用的基本机制.
- 在DN处理的背景下探索MSP的结构-活动关系.
主要方法:
- 对研究MSP及其对糖尿病病的影响的文献综述.
- 对研究的分析,重点是MSP的生物活动和机制.
- 检查与MSP和DN相关的结构-活动关系研究.
主要成果:
- 在体内和体外,MSP在治疗糖尿病病方面表现出显著的潜力.
- 关键的机制包括对炎症途径的调节,抗氧化作用,以及对球损伤的保护.
- 结构-活性关系研究强调了硫化模式和分子重量对疗效的重要性.
结论:
- 海洋硫酸多糖 (MSP) 是治疗糖尿病病 (DN) 的有前途的天然产品类.
- 了解结构-活动关系对于开发有效的MSP为DN的疗法至关重要.
- 对MSP的进一步研究可能会导致用于管理DN的新型治疗策略.
相关概念视频
01:17Oral Hypoglycemic Agents: Sulfonylureas
210
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
210
01:22Heart Failure Drugs: Diuretics
384
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
384
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
204
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
204